Literature DB >> 15131464

Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002.

Kevin Purcell1, Jaime Fergie.   

Abstract

BACKGROUND: Treatment of respiratory syncytial virus (RSV) lower respiratory tract infection has historically been one of the most frequent reasons for admission to Driscoll Children's Hospital.
OBJECTIVE: The objective of this study was to examine the relationship of risk factors for a severe and complicated disease course to the treatment and hospital length of stay.
METHODS: Subjects were identified through a retrospective review of the medical records of all patients discharged with a diagnosis of RSV lower respiratory tract infection during 9 of the 11 RSV seasons between July 1, 1991 and June 30, 2002. The RSV seasons from 1991-1992 to 1994-1995 were compared with the RSV seasons from 1995-1996 to 2001-2002 with regard to treatment and hospital course.
RESULTS: There were a total of 3308 admissions. Compared with patients with no risk factors, higher percentages of patients with age <6 weeks, history of prematurity, congenital heart disease and neurologic disease were admitted to the pediatric intensive care unit (PICU) and required mechanical ventilation (P < 0.001). Also the hospital length of stay was longer for patients with each of these individual risk factors (P < 0.001). The hospital length of stay and the percentages of patients admitted to the PICU and requiring on mechanical ventilation increased as the number of risk factors increased from zero to 3 or more (P < 0.001). Of patients with 3 or more risk factors, the average hospital length of stay was 13.5 days; 67% were admitted to the PICU, and 47% required mechanical ventilation. Ribavirin use decreased in patients with each of the individual risk factors (P < 0.001) as well as in patients with one or more risk factors (P < 0.001). At the same time the PICU admission rate increased from 6.1% to 11.2% (P < 0.001).
CONCLUSIONS: Patients with three or more risk factors were at very high risk for having a severe or complicated disease course associated with admission to the PICU, placement on mechanical ventilation and a longer hospital length of stay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131464     DOI: 10.1097/01.inf.0000126273.27123.33

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  33 in total

Review 1.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

Review 2.  Bronchiolitis.

Authors:  Thomas Bourke; Michael Shields
Journal:  BMJ Clin Evid       Date:  2011-04-11

3.  Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis.

Authors:  D Hervás; J Reina; A Yañez; J M del Valle; J Figuerola; J A Hervás
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-13       Impact factor: 3.267

4.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

5.  Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus.

Authors:  Michele Y F Kong; John P Clancy; Ning Peng; Yao Li; Tomasz J Szul; Xin Xu; Robert Oster; Wayne Sullender; Namasivayam Ambalavanan; J Edwin Blalock; Amit Gaggar
Journal:  Eur Respir J       Date:  2013-12-05       Impact factor: 16.671

6.  Comparison of Intravenous Palivizumab and Standard of Care for Treatment of Respiratory Syncytial Virus Infection in Mechanically Ventilated Pediatric Patients.

Authors:  Brady J Helmink; Carolyn E Ragsdale; Evan J Peterson; Kathryn G Merkel
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

7.  Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus.

Authors:  Neal J Thomas; Susan DiAngelo; Joseph C Hess; Ruzong Fan; Margaret W Ball; Joseph M Geskey; Douglas F Willson; Joanna Floros
Journal:  Pediatr Res       Date:  2009-07       Impact factor: 3.756

Review 8.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

Review 9.  Bronchiolitis.

Authors:  Juan Manuel Lozano
Journal:  BMJ Clin Evid       Date:  2007-10-10

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.